You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for Patent: 8,241,664

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,241,664 protect, and when does it expire?

Patent 8,241,664 protects JATENZO and is included in one NDA.

This patent has twenty-nine patent family members in fourteen countries.

Summary for Patent: 8,241,664

Title:	Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
Abstract:	A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.
Inventor(s):	Dudley; Robert E. (Rosemary Beach, IL), Constantinides; Panayiotis P. (Gurnee, IL)
Assignee:	Clarus Therapeutics, Inc (Northbrook, IL)
Application Number:	11/911,446
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,241,664
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 8,241,664

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Tolmar	JATENZO	testosterone undecanoate	CAPSULE;ORAL	206089-001	Mar 27, 2019		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			METHOD OF TREATING TESTOSTERONE DEFICIENCY	⤷ Sign Up
Tolmar	JATENZO	testosterone undecanoate	CAPSULE;ORAL	206089-002	Mar 27, 2019		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			METHOD OF TREATING TESTOSTERONE DEFICIENCY	⤷ Sign Up
Tolmar	JATENZO	testosterone undecanoate	CAPSULE;ORAL	206089-003	Mar 27, 2019		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			METHOD OF TREATING TESTOSTERONE DEFICIENCY	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 8,241,664

PCT Information
PCT Filed	April 14, 2006	PCT Application Number:	PCT/US2006/014207
PCT Publication Date:	October 26, 2006	PCT Publication Number:	WO2006/113505

International Family Members for US Patent 8,241,664

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006236564	⤷ Sign Up
Australia	2011201422	⤷ Sign Up
Brazil	PI0607549	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.